Alzamend Neuro, Inc. ALZN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -9.10M | -8.77M | -7.04M | -5.83M | -6.24M |
| Total Depreciation and Amortization | 110.80K | 110.80K | 95.80K | 80.80K | 65.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 741.80K | 707.50K | 165.00K | 237.00K | 286.80K |
| Change in Net Operating Assets | 1.40M | -113.70K | 821.90K | -135.60K | -1.98M |
| Cash from Operations | -6.84M | -8.07M | -5.96M | -5.65M | -7.88M |
| Capital Expenditure | -- | -- | -210.00K | -210.00K | -210.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -210.00K | -210.00K | -210.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.46M | 794.80K | 841.70K | 1.53M | 2.70M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 7.35M | 4.04M | 4.68M | 4.68M | 9.81M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 8.81M | 4.83M | 5.52M | 6.21M | 12.51M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.97M | -3.24M | -645.00K | 356.40K | 4.43M |